Has change come to biology?
By John Timmer,
arts technica
| 02. 02. 2009
Stem cell research under Obama
President Obama's promise to restore science to its rightful place has raised the hopes of biologists that there will be swift action on what many view as a serious hindrance to biology: restrictions on the use of human embryonic stem cells (hESCs). Federal funding of hESC research has been limited to lines created before August 9th, 2001—nearly nine years ago—and most of the acceptable lines have since been found to be inappropriate for clinical research; ethical issues involving informed consent affect the remaining handful. On Tuesday, the New York Stem Cell foundation hosted a panel that discussed how a lifting of the Bush-era restrictions on hESC research is likely to change hESC research.
The panel included two members that had been part of the Obama transition team: Alta Charo, who focuses on bioethics at the University of Wisconsin Law School, and Nobel Laureate Harold Varmus of Sloan-Kettering, who is now serving on Obama's Science and Technology advisory panel. Lawrence Tabak of the NIH provided some perspective on what his agency would need to do, and Harvard's Kevin Eggan spoke as...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...